{"slideshow_credits": null, "snippet": "The drug company GlaxoSmithKline hopes that making its research available to scientists will lead to safer, more effective drugs.", "abstract": "GlaxoSmithKline plans to open up much of its drug research to scientists, hoping it will lead to safer, more effective drugs; move, first for a major drug firm, is apparent effort to deflect criticism that important clinical trial information often is not disclosed.", "section_name": "Business Day", "print_page": "1", "document_type": "article", "byline": {"person": [{"firstname": "Katie", "role": "reported", "lastname": "THOMAS", "rank": 1, "organization": ""}], "original": "By KATIE THOMAS", "contributor": ""}, "web_url": "http://www.nytimes.com/2012/10/11/business/glaxo-opens-door-to-data-on-its-research.html", "lead_paragraph": "The drug company GlaxoSmithKline hopes that making its research available to scientists will lead to safer, more effective drugs.", "headline": {"seo": "Glaxo Opens Door to Data on Its Research", "main": "Glaxo Opens Door to Data on Research", "print_headline": "Glaxo Opens Door to Data On Research"}, "_id": "507c4e8e95e998af7118624a", "word_count": "881", "multimedia": [], "pub_date": "2012-10-11T00:00:00Z", "source": "The New York Times", "news_desk": "Business", "keywords": [{"value": "Drugs (Pharmaceuticals)", "name": "subject", "is_major": "Y", "rank": "1"}, {"value": "GlaxoSmithKline PLC", "name": "organizations", "is_major": "Y", "rank": "2"}, {"value": "Research", "name": "subject", "is_major": "N", "rank": "3"}, {"value": "Clinical Trials", "name": "subject", "is_major": "Y", "rank": "4"}, {"value": "Avandia (Drug)", "name": "subject", "is_major": "N", "rank": "5"}, {"value": "Paxil (Drug)", "name": "subject", "is_major": "N", "rank": "6"}], "blog": [], "subsection_name": null, "type_of_material": "News"}